Medica EasyStat - An Ideal Option for a Demanding Health Care EnvironmentNovember 16th, 2018
World Diabetes Day 2018 – Focus on the Role of the Family in Fighting DiabetesNovember 14th, 2018
MEDICA 2018 - World Forum for Medicine
Düsseldorf, GermanyBooth No.: 3/D35-2
AACC Annual Scientific Meeting and Clinical Lab Expo
ChicagoBooth No.: 3849
Thanks to Block Scientific, I was able to procure the re-certified Bayer DCA 2000+ without hassles and get the lab back in operation. The
device works perfectly and I look forward to doing more business with Block Scientific.
--- Mathew Anderson, New Jersey
The Sperm Antibody ELISA is a reliable and quantitative test for the determination of antibodies directed against human spermatozoa. This test is intended for the use with serum.
The Sperm Antibody ELISA (Enzyme Linked ImmunoSorbent Assay) is a solid-phase sandwich enzyme-immunoassay for the quantitative determination of anti-spermatozoa antibodies in human serum. The ELISA-plate is coated with a mix of spermatozoa proteins which are recognized by anti-spermatozoa antibodies. The samples and standards are pipetted into the wells and then incubated. During this incubation anti-spermatozoa antibodies bind to the spermatozoa proteins and are thus immobilised on the plate. After washing the enzyme conjugate, consisting of anti-human globulin antibodies covalently coupled to horseradish peroxidase, is added.
After removal of the unbound conjugate by washing the horseradish peroxidase oxidizes the then added substrate TMB (3,3’,5,5’-tetramethylbenzidine) yielding a colour reaction which is stopped with 0.25 M sulphuric acid (H2SO4). The extinction is measured at a wavelength of 450 nm with a microplate reader. The use of a reference measurement with a wavelength ≥550 nm is
recommended. Antibodies directed against spermatozoa antigens may cause infertility in women or men. The application of the Anti-Spermatozoa Antibody ELISA is recommended for the diagnosis of immunologically caused disorders of fertility.
Unwanted childlessness is a growing problem with which up to 20% of all couples in the reproductive age are confronted temporarily or long-term. In 20% of these cases the presence of anti-spermatozoa antibodies in the male or the female patient is detectable (Lahteenmaki A et al: Hum Reprod (1995) 10, 2824-28; Nagy ZP et al: Hum Reprod (1995) 10, 1775-80).
The definition of infertility according to the WHO (WHO Laboratory Manual for the Examination of Human Semen and Semen Cervical-Mucus Interaction, 1999) is the absence of a conception within 12 months of unprotected intercourse. The main cause of an immunological fertility disorder is the formation of antibodies directed against spermatozoa antigens.
Anti-spermatozoa antibodies exert heterogeneous effects on the ability of spermatozoa to fertilize. The inhibiting effect of anti-spermatozoa antibodies on the motility of spermatozoa by binding to their surface and by agglutinating processes is well-known (Zouari R et al: Fertil Steril (1993) 59, 606-12). The penetration of the spermatozoa into the cervical mucus is impaired by the presence of anti-spermatozoa antibodies in the seminal plasma and/or in the cervical mucus (Eggert-Kruse W et al: Hum Reprod (1993) 8, 1025-31). Antispermatozoa antibodies negatively influence the capacitation and the acrosome reaction of spermatozoa and thereby impede the interaction of the spermatozoa with the oocyte (Francavilla F et al: Front Biosci (1999): 1;4:9-25; Bohring C et al.: Hum Reprod (2001) 7:113-8).
The interaction of the spermatozoon with the oocyte and the subsequent binding to and penetration of the zona pellucida may be inhibited by anti-spermatozoa antibodies. The following fusion of the oocyte and a spermatozoon may also be impaired by the presence of anti-spermatozoa antibodies (Mazumdar S et al.: Fertil Steril (1998) 70, 799-810; Kutteh
WH: Hum Reprod, (1999) 14, 2426-9). According to Crosignani et al. (Crosignani et al.: PG et al.: Hum Reprod (1998) 13, 2025-32) the rate of pregnancies in couples with anti-spermatozoa antibodies on the part of the man or the woman are 38% lower compared to the control
groups. Furthermore an influence on the implantation and on the early embryological development could be confirmed.
An association of anti-spermatozoa antibodies and miscarriages is discussed. The frequency of anti-spermatozoa antibodies in infertile couples amounts to 20% (Lahteenmaki A et al.: Hum Reprod (1995) 10, 2824-28; Nagy ZP et al.: Hum Reprod (1995) 10, 1775-80). Anti-spermatozoa antibodies may occur dissolved in the ejaculate or bound to the surface of spermatozoa. Antispermatozoa
antibodies may be found in men and in women (Clarke GN et al.: Am J Reprod Immunol Microbiol (1985) 7, 143-7). In women anti-spermatozoa antibodies may be found in cervical mucus, oviduct liquid and follicular liquid.